18.06.2023, 2190 Zeichen

Croma-Pharma: Croma-Pharma®, an Austrian based global player in the minimally invasive aesthetics market, announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial1 is being led by Lanhzou Biotechnique Development with the intention to confirm the efficacy and safety of Princess® Volume Plus Lidocaine in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants. The trial is organised and executed by the clinical research organisation Beijing World-Clinical Research Biotechnology Development; the plan is to enroll 15 clinical centres and approximately 600 patients targeting mid-facial augmentation.

Valneva: Valneva, a specialty vaccine company, announces that the Company’s pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, have been published in The Lancet , the world’s leading peer-reviewed medical journal. Juan Carlos Jaramillo, Chief Medical Officer of Valneva, said, “This publication in the Lancet underlines the strength of VLA1553’s scientific approach and is consistent with the quality of our pivotal Phase 3 study. We are pleased that more detailed results on our single-shot chikungunya vaccine candidate are now available to the scientific and broader public health communities.”
Valneva: weekly performance: 12.27%

Andritz: International technology group Andritz has installed a new spunlace pilot line at its center of competence in Montbonnot, France. It allows customers and partners to conduct trials for producing nonwovens from recycled and/or natural fibers such as hemp, flax, and cotton. The new pilot line features optimized web forming and entanglement for smooth processing of sensitive and irregular fibers. The innovative card set-up is designed to protect and maintain the quality of the fibers while achieving outstanding productivity rates.
Andritz: weekly performance: -2.71%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/06/2023)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 113/365: Was StudentInnen der Wirtschaftsuni Wien zur Wiener Börse sagen

Bildnachweis

Aktien auf dem Radar:Palfinger, CPI Europe AG, Frequentis, RHI Magnesita, Rosenbauer, Kapsch TrafficCom, VIG, OMV, Uniqa, voestalpine, Zumtobel, Andritz, AT&S, Lenzing, Bawag, DO&CO, Erste Group, RBI, Wolford, Agrana, Oberbank AG Stamm, Warimpex, Polytec Group, Amag, Flughafen Wien, Österreichische Post, Telekom Austria, ATX.

---